Invasive Meningococcal Disease in a Patient With Complement 7 Deficiency
ABSTRACT Neisseria meningitidis can cause invasive meningococcal disease (IMD). Individuals with primary complement deficiencies are at a higher risk of developing IMD. However, cases of IMD associated with complement deficiency have rarely been reported in Japan.
Hiroaki Nishioka +2 more
wiley +1 more source
Neutropenia as an adverse event following vaccination : results from randomized clinical trials in healthy adults and systematic review [PDF]
Background : In the context of early vaccine trials aimed at evaluating the safety profile of novel vaccines, abnormal haematological values, such as neutropenia, are often reported.
Aerssens, Annelies +10 more
core +4 more sources
ABSTRACT This descriptive observational study based on post‐marketing surveillance data evaluates adverse events following immunization (AEFI) associated with the TAK‐003 (Qdenga®) vaccine. Conducted in Dourados, Brazil, between January and November 2024, the study aimed to assess the frequency, nature, and severity of AEFI to inform public health ...
Luana Clemm Kuhnen Anschau +9 more
wiley +1 more source
EPIDEMIOLOGY AND PREVENTION OF MENINGOCOCCAL DISEASE: A CRITICAL APPRAISAL OF VACCINE POLICIES
Meningococcal disease is characterized by a marked variation in incidence and serogroup distribution by region and over time. In several European countries, Canada and Australia, immunization programs, including universal vaccination of infants or ...
Marco AP Safadi, E David G Mcintosh
doaj +1 more source
Preventive measures in infancy to reduce under-five mortality: a case-control study in The Gambia.
OBJECTIVE: To investigate the relationship between child mortality and common preventive interventions: vaccination, trained birthing attendants, tetanus toxoid during pregnancy, breastfeeding and vitamin A supplementation. METHODS: Case-control study in
Adegbola, Richard A +8 more
core +1 more source
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England [PDF]
Serum samples from children immunized with a meningococcal serogroup B vaccine demonstrated potent serum bactericidal antibody activity against the hypervirulent Neisseria meningitidis serogroup W strain circulating in England. The recent introduction of
Alessia Biolchi +21 more
core +2 more sources
Fusobacterium nucleatum in Health and Disease
Fusobacterium nucleatum (Fn), an oral commensal and opportunistic pathogen, primarily colonizes the oral cavity. It contributes to multiple nonmalignant diseases and cancers—especially colorectal cancer—through interaction with the host and other microbes, leading to inflammation, enhanced cellular proliferation, metastatic progression, and immune ...
Xinyi Yang +3 more
wiley +1 more source
Polyhydroxyalkanoate beads as a particulate vaccine against Streptococcus pneumoniae and Neisseria meningitidis : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Microbiology at Massey University, Manawatu, New Zealand [PDF]
Listed in 2018 Dean's List of Exceptional ThesesStreptococcus pneumoniae and Neisseria meningitidis are the major causes of pneumonia and meningitis, respectively, worldwide.
González Miró, Majela
core
UK parents' attitudes towards meningococcal group B (MenB) vaccination: a qualitative analysis [PDF]
OBJECTIVES: (1) To explore existing knowledge of, and attitudes, to group B meningococcal disease and serogroup B meningococcal (MenB) vaccine among parents of young children. (2) To seek views on their information needs.
Bedford, H +3 more
core +1 more source
Immunogenicity and safety of combined tetanus, reduced diphtheria, acellular pertussis vaccine when co-administered with quadrivalent meningococcal conjugate and human papillomavirus vaccines in healthy adolescents. [PDF]
Objective: Current United States immunization recommendations for adolescents include vaccines against tetanus, diphtheria and pertussis (Tdap), human papillomavirus (HPV), and Neisseria meningitidis serogroups A, C, W-135, and Y. In this Phase IV study,
Alexanderian, David +8 more
core +1 more source

